Clinical Study

Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Table 4

Liver function and lipid Profile in the three groups at baseline and during treatment.

Baseline8 weeks16 weeks24 weeks

ALT (U/L)
 Group 186.75 ± 27.5974.22 ± 29.0967.19 ± 27.4063.04 ± 26.80
 Group 290.79 ± 28.1351.03 ± 21.1839.70 ± 14.3740.45 ± 16.30
 Group 391.64 ± 28.6151.80 ± 21.2234.07 ± 14.5532.23 ± 16.18
AST (U/L)
 Group 167.28 ± 34.6860.19 ± 25.5756.16 ± 22.6653.38 ± 29.81
 Group 269.38 ± 35.7941.64 ± 15.2032.98 ± 11.7832.06 ± 10.41
 Group 369.60 ± 36.0043.72 ± 16.3531.33 ± 13.6825.91 ± 13.82
GGT (U/L)
 Group 188.96 ± 43.0270.71 ± 31.8164.23 ± 27.8559.53 ± 32.38
 Group 290.29 ± 37.1253.92 ± 19.0943.68 ± 13.2443.32 ± 22.63
 Group 393.27 ± 34.9859.70 ± 27.2040.02 ± 116.7533.57 ± 16.07
CB (µmol/L)
 Group 15.14 ± 3.104.26 ± 2.113.51 ± 1.703.07 ± 1.80
 Group 26.52 ± 4.184.35 ± 2.583.59 ± 1.463.60 ± 2.36
 Group 36.45 ± 3.405.63 ± 2.543.57 ± 1.794.09 ± 3.12
TB (µmol/L)
 Group 115.77 ± 6.2913.66 ± 4.4612.17 ± 3.959.81 ± 4.87
 Group 215.31 ± 6.7912.76 ± 5.3511.40 ± 3.3612.16 ± 4.83
 Group 317.25 ± 7.7215.12 ± 4.1411.78 ± 3.8911.04 ± 4.92
TG (mmol/L)
 Group 12.97 ± 1.212.08 ± 0.821.87 ± 0.921.82 ± 0.96
 Group 23.07 ± 1.042.40 ± 0.902.02 ± 0.641.80 ± 0.78
 Group 33.24 ± 1.212.12 ± 0.801.88 ± 0.611.33 ± 0.57
TC (mmol/L)
 Group 16.57 ± 1.715.33 ± 1.194.79 ± 0.855.22 ± 1.22
 Group 26.39 ± 1.735.89 ± 0.875.28 ± 1.285.44 ± 1.19
 Group 36.62 ± 1.715.65 ± 0.964.95 ± 1.184.38 ± 1.47
HDL-C (mmol/L)
 Group 10.91 ± 0.300.98 ± 0.281.05 ± 0.301.14 ± 0.39
 Group 20.94 ± 0.280.98 ± 0.311.02 ± 0.331.09 ± 0.39
 Group 30.95 ± 0.281.03 ± 0.291.15 ± 0.311.32 ± 0.35
LDL-C (mmol/L)
 Group 14.09 ± 1.343.94 ± 1.473.85 ± 1.643.59 ± 1.50
 Group 23.95 ± 1.023.87 ± 1.593.72 ± 1.343.66 ± 1.50
 Group 34.15 ± 0.873.81 ± 0.593.71 ± 1.092.80 ± 1.35